Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319648 | 1.00 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL15318934 | 1.00 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL6444864 | 0.86 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL2615731 | 0.86 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL6444859 | 0.86 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL30537712 | 0.86 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL13964503 | 0.86 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL25305199 | 0.85 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL10211199 | 0.85 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL30484720 | 0.85 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-108699052-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10344056-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344056-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | SPHK1 2325/4885BRD4 1334/4885CHRM2 2439/4885 |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | SPHK1 2263/4885BRD4 2833/4885CHRM2 2163/4885 |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | SPHK1 2325/4885BRD4 1334/4885CHRM2 2439/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | SPHK1 2325/4885BRD4 1334/4885CHRM2 2439/4885 |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | SPHK1 2325/4885BRD4 1334/4885CHRM2 2439/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | SPHK1 2325/4885BRD4 1334/4885CHRM2 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.